LeMaitre Vascular (NASDAQ:LMAT) Releases Q2 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMATGet Rating) updated its second quarter earnings guidance on Thursday. The company provided earnings per share guidance of $0.32 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.38. The company issued revenue guidance of $41.100 million, compared to the consensus revenue estimate of $42.54 million.LeMaitre Vascular also updated its FY22 guidance to $1.26 EPS.

A number of equities research analysts have recently weighed in on the stock. Barrington Research dropped their price objective on shares of LeMaitre Vascular from $54.00 to $50.00 in a report on Friday. Zacks Investment Research raised shares of LeMaitre Vascular from a hold rating to a buy rating and set a $50.00 price objective on the stock in a report on Thursday. Finally, StockNews.com assumed coverage on shares of LeMaitre Vascular in a report on Thursday, March 31st. They set a hold rating on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $58.60.

NASDAQ LMAT traded down $2.60 on Friday, reaching $43.21. 402,893 shares of the company’s stock traded hands, compared to its average volume of 158,020. The firm has a market cap of $948.46 million, a price-to-earnings ratio of 34.57, a P/E/G ratio of 3.20 and a beta of 1.32. The stock has a 50 day moving average price of $45.73 and a 200-day moving average price of $47.50. LeMaitre Vascular has a fifty-two week low of $39.48 and a fifty-two week high of $64.50.

LeMaitre Vascular (NASDAQ:LMATGet Rating) last posted its earnings results on Thursday, April 28th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $39.56 million for the quarter, compared to analyst estimates of $38.65 million. LeMaitre Vascular had a net margin of 17.42% and a return on equity of 12.42%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 earnings per share. On average, analysts expect that LeMaitre Vascular will post 1.39 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 2nd. Investors of record on Tuesday, May 17th will be given a dividend of $0.125 per share. The ex-dividend date of this dividend is Monday, May 16th. This represents a $0.50 dividend on an annualized basis and a yield of 1.16%. LeMaitre Vascular’s dividend payout ratio is presently 40.00%.

In related news, insider Trent G. Kamke sold 7,929 shares of the business’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $48.22, for a total transaction of $382,336.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 16.50% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in shares of LeMaitre Vascular by 1.0% in the fourth quarter. BlackRock Inc. now owns 3,147,424 shares of the medical instruments supplier’s stock worth $158,097,000 after acquiring an additional 31,590 shares during the period. Geode Capital Management LLC raised its position in shares of LeMaitre Vascular by 5.7% during the 4th quarter. Geode Capital Management LLC now owns 354,487 shares of the medical instruments supplier’s stock worth $17,805,000 after purchasing an additional 18,983 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of LeMaitre Vascular by 8.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 238,521 shares of the medical instruments supplier’s stock worth $12,663,000 after purchasing an additional 18,670 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of LeMaitre Vascular by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 157,799 shares of the medical instruments supplier’s stock worth $7,926,000 after purchasing an additional 1,756 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of LeMaitre Vascular by 5.2% during the 4th quarter. Legal & General Group Plc now owns 46,075 shares of the medical instruments supplier’s stock worth $2,314,000 after purchasing an additional 2,274 shares during the last quarter. Institutional investors and hedge funds own 85.82% of the company’s stock.

About LeMaitre Vascular (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Featured Stories

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.